ArticlePloS one2012
The potential role of ORM2 in the development of colorectal cancer.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Meta-analysis of gene expression profiles identifies differential biomarkers for hepatocellular carcinoma and cholangiocarcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Pooled it
- Safety, pharmacokinetics and pharmacogenetics of a single ascending dose of pradefovir, a novel liver-targeting, anti-hepatitis B virus drug, in healthy Chinese subjects.Hepatology international · 2017Trial
- Orosomucoid 2 promotes colorectal cancer liver metastasis by suppressing natural killer cell-mediated antitumor immunity by remodeling the serine and one-carbon metabolism pathway.Molecular cancer · 2026Article
- Orosomucoid 2 upregulation mediates liver injury-induced colorectal cancer liver metastasis by promoting EMT and cell migration.Cancer science · 2025Article
- Circulating large extracellular vesicles as diagnostic biomarkers of indeterminate thyroid nodules: multi-platform omics analysis.BJS open · 2024Article
- Quercetin suppresses cell viability in triple-negative breast cancer by targeting ORM2.American journal of cancer research · 2024Article
- Diagnostic role of plasma ORM2 in differentiating prostate cancer from benign prostatic hyperplasia.Journal of cancer research and clinical oncology · 2023Article
- Screening and verification of genes related to polycystic ovary syndrome.The Journal of international medical research · 2023Article
- Aging Alters the Aortic Proteome in Health and Thoracic Aortic Aneurysm.Arteriosclerosis, thrombosis, and vascular biology · 2022Article
- Biomarker Candidates for Tumors Identified from Deep-Profiled Plasma Stem Predominantly from the Low Abundant Area.Journal of proteome research · 2022Article
- Article
- Web-based transcriptome analysis determines a sixteen-gene signature and associated drugs on hearing loss patients: A bioinformatics approach.Journal of clinical laboratory analysis · 2021Article
- Severe types of fetopathy are associated with changes in the serological proteome of diabetic mothers.Medicine · 2021Observational
- Article
- Molecular alterations in oral cancer between tobacco chewers and smokers using serum proteomics.Cancer biomarkers : section A of Disease markers · 2021Article
- Colorectal cancer is associated with increased circulating lipopolysaccharide, inflammation and hypercoagulability.Scientific reports · 2020Article
- Downregulation of orosomucoid 2 acts as a prognostic factor associated with cancer-promoting pathways in liver cancer.World journal of gastroenterology · 2020Article
- Revelation of Proteomic Indicators for Colorectal Cancer in Initial Stages of Development.Molecules (Basel, Switzerland) · 2020Article
- Early diagnosis of colorectal cancer via plasma proteomic analysis of CRC and advanced adenomatous polyp.Gastroenterology and hepatology from bed to bench · 2019Article
- iTRAQ-based quantitative proteomic analysis and bioinformatics study of proteins in retinoblastoma.Oncology letters · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is the third most common malignancy in the world. The risk of death is closely correlated to the stage of CRC at the time of primary diagnosis. Therefore, there is a compelling need for the identification of blood biomarkers that can enable early detection of CRC. We used a quantitative proteomic approach with isobaric labeling (iTRAQ) to examine changes in the plasma proteome of 10 patients with CRC compared to healthy volunteers. Enzyme-Linked Immunosorbnent Assay (ELISA) and Western blot were used for further validation. In our quantitative proteomics analysis, we detected 75 human plasma proteins with more than 95% confidence using iTRAQ labeling in conjunction with microQ-TOF MS. 9 up-regulated and 4 down-regulated proteins were observed in the CRC group. The ORM2 level in plasma was confirmed to be significantly elevated in patients suffering from CRC compared with the controls. ORM2 expression in CRC tissues was significantly increased compared with that in corresponding adjacent normal mucous tissues (P<0.001). ITRAQ together with Q-TOF/MS is a sensitive and reproducible technique of quantitative proteomics. Alteration in expression of ORM2 suggests that ORM2 could be used as a potential biomarker in the diagnosis of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.